All U.S. adults now eligible for Pfizer and Moderna Covid vaccine booster shots after CDC gives final OK
- CDC Director Rochelle Walensky signed off on an independent panel's recommendation for all U.S. adults to be eligible for Pfizer and Moderna booster shots.
- Pfizer said its booster dose was 95% effective at preventing symptomatic infection in people who had no evidence of prior infection in a clinical trial of 10,000 participants 16 and older.
- While more than 195 million people are fully vaccinated in the U.S., Covid cases are rising in some areas as the effectiveness of the vaccines declines over time.
All adults in the U.S. are now eligible to receive Pfizer's and Moderna's Covid vaccine boosters, after the Centers for Disease Control and Prevention authorized the shots for the general public Friday. The move allows an extra dose of protection for tens of millions of fully vaccinated Americans as cases climb and public officials worry the nation could face another surge during the winter.
CDC Director Rochelle Walensky signed off on the booster shots hours after the agency's independent panel of vaccine scientists unanimously endorsed opening up eligibility to everyone 18 and older at least six months after they received their second dose.
The Food and Drug Administration had authorized both companies' vaccine boosters for all U.S. adults earlier Friday.
"After critical scientific evaluation, today's unanimous decision carefully considered the current state of the pandemic, the latest vaccine effectiveness data over time, and review of safety data from people who have already received a COVID-19 primary vaccine series and booster," Walensky said in a statement Friday evening.
"Booster shots have demonstrated the ability to safely increase people's protection against infection and severe outcomes and are an important public health tool to strengthen our defenses against the virus as we enter the winter holidays. Based on the compelling evidence, all adults over 18 should now have equitable access to a COVID-19 booster dose," Walensky said.
The CDC also said people over the age of 50 should get booster shots, a stronger recommendation for that age group than before. The panel previously limited its strongest guidance to people over 65 and other people with high risk.
Pfizer said its booster dose was 95% effective at preventing symptomatic infection in people who had no evidence of prior infection in a clinical trial of 10,000 participants 16 years and older, according to Dr. John Perez, vice president of the company's vaccine clinical research program.
Moderna didn't submit its efficacy data for its booster, telling the panel it was still gathering the data.
While more than 195 million people are fully vaccinated in the U.S., Covid cases are rising in some areas as the effectiveness of the vaccines falls over time, the CDC's Dr. Sara Oliver told the panel.
"Overall protection remains high for severe disease and hospitalization and waning [effectiveness] appears to be less pronounced for the Moderna vaccine compared to Pfizer," Oliver said. However, she said evidence suggests there is a higher risk for a rare heart condition called myocarditis following Moderna's shots compared with Pfizer.
Dr. Nirav Shah, director of Maine's CDC and president of the Association of State and Territorial Health Officials, said the current guidelines are confusing and generate more work for state and local health officials who have to determine who's eligible. The group wants the CDC to distribute the shots to everyone 18 and older to streamline the eligibility process, he said.
"Such a move has the benefit of easing pressure on state health department immunization program staff, who are now fielding a high volume of booster eligibility questions," he told the panel.
"As a clinician deep in the clinical trenches, I am really glad that we have clarity and streamlining of the recommendation so that all Americans can understand the vaccines that are recommended for them at this time," committee member Dr. Camille Kotton said after the vote.
Side effects from both Pfizer's and Moderna's third shots were mild in the overwhelming majority of study participants, including pain at the injection site, headaches, fever and chills, according to the data.
Moderna found the side effects from its booster doses were comparable to those experienced by patients after the initial two-dose series, including headaches, fatigue and muscle aches and pains. However, the company is still gathering safety data as its clinical trial of more than 15,000 participants is ongoing, according to Rituparna Das, who presented on behalf of Moderna during the meeting.
The CDC, in a study presented Friday, found 54 preliminary cases of myocarditis and myopericarditis among nearly 26 million Pfizer and Moderna booster doses administered, or about 2.1 cases per 1 million shots administered. However, only 12 of those reported cases have been attributed to the vaccines so far while 38 are under review and four were ruled out.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart. When the two conditions occur together, they are called myopericarditis.
The CDC also found that people reported fewer side effects of any kind from Pfizer and Moderna boosters than from the primary two-dose series.
The CDC advisory panel originally declined in September to endorse Pfizer's boosters for the broader public, supporting instead a scaled-back distribution plan for elderly Americans and people who face a high risk from Covid infection due to underlying health conditions.
At that time, experts on the panel said available safety data, based on research from 306 individuals who received boosters, was too limited to make a determination about the risks posed by rare side effects such as myocarditis.
"At the time we met, there was less information available. It's always a balance between safety and efficacy," Dr. Ofer Levy, the director of the Precision Vaccines Program at Boston Children's Hospital and a voting member on the FDA's vaccine advisory board, said in an interview with CNBC on Friday. "We have more data now, and the data indicate, number one, that although myocarditis is an unusual risk, it's usually mild and it can be handled."
He said scientists also have more data on breakthrough infections in fully immunized people that indicates protection declines over time.
The panel endorsed Moderna's boosters for elderly Americans and people with underlying health conditions in October as well as Johnson & Johnson boosters for everyone age 18 and over.
Broadly administering booster doses is a controversial topic in public health. The World Health Organization has repeatedly criticized wealthy nations for rolling out third shots at a time when people in poorer nations have very limited access to vaccines.
Some experts in the U.S. are also questioning whether now is the time to start administering third shots when more than 60 million Americans still haven't received their first dose.
However, state officials from California to Maine had already started rolling out boosters for all adults before the CDC's authorization Friday.
Many vaccinated Americans want an extra layer of protection as data increasingly shows that vaccine effectiveness against infection declines over time. Public health experts expect an increase in infection as Americans head indoors to escape the winter cold and gather with families over the holidays.
Booster doses could help reduce transmission by helping to prevent breakthrough infections in people who are already vaccinated.
An 81-year-old brain doctor's 7 'hard rules' for keeping your memory 'sharp as a whip'
How much money you’d have if you invested $1,000 into McDonald's 10 years ago
How a $220 million mistake turned Kind Snacks into a $5 billion company
Early retiree says breaking these 6 ‘society rules’ helped him save $1 million: ‘I wasn't born rich'
Don't risk a tax audit. Here are four reasons the IRS may flag your return